Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for RNA-targeted medicines

Tue Apr 16, 2013 2:00am EDT

* Reuters is not responsible for the content in this press release.

Santaris Pharma announces a worldwide discovery alliance with Bristol-Myers Squibb for
RNA-targeted medicines

HOERSHOLM, Denmark, and SAN DIEGO, April 16, 2013 /PRNewswire/ -- Santaris Pharma A/S, a
privately held biopharmaceutical company focused on developing medicines targeted to
disease-related mRNAs and microRNAs, today announced a worldwide strategic alliance with
Bristol-Myers Squibb (NYSE : BMY) to discover and develop novel medicines using Santaris
Pharma's proprietary Locked Nucleic Acid (LNA) Drug Platform.

(Logo: http://photos.prnewswire.com/prnh/20100111/SPLOGO
[http://photos.prnewswire.com/prnh/20100111/SPLOGO]) 

Under the terms of the agreement, Santaris Pharma will receive an upfront payment of $10
million, up to $90 million in potential milestone payments per product and funding of
ongoing discovery and research activities. In addition, Santaris Pharma will be eligible
to receive royalties on the worldwide sales of all medicines arising from the alliance. 

Announcing the alliance, President and CEO of Santaris Pharma, Henrik Stage, said: "We
are delighted to welcome Bristol-Myers Squibb as a new partner. This strategic alliance
further consolidates Santaris Pharma's leadership in the field of oligonucleotide
therapeutics." 

Dr Henrik Oerum, Santaris Pharma's Chief Scientific Officer and VP Business Development
commented: "We are proud and honored that Bristol-Myers Squibb has chosen Santaris
Pharma as their partner. We are confident that the unique features of the LNA Drug
platform can achieve clinical breakthroughs and look forward to working closely with the
Bristol-Myers Squibb team." 

About Locked Nucleic Acid (LNA) Drug Platform

The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S
combines the company's proprietary LNA chemistry with its highly specialized and
targeted drug development capabilities to rapidly deliver LNA-based drug candidates
against RNA targets, both mRNA and microRNA, for a range of diseases including
infectious and inflammatory diseases, cardiometabolic disorders, cancer and rare genetic
disorders. LNA-based drugs are a promising new class of therapeutics that are enabling
scientists to develop drug candidates that target previously inaccessible clinical
pathways. The LNA Drug Platform overcomes the limitations of earlier antisense and siRNA
technologies to deliver potent single-stranded LNA-based drug candidates across a
multitude of disease states. The unique combination of small size and very high affinity
allows this new class of drug candidates to potently and specifically inhibit RNA
targets in many different tissues without the need for complex delivery vehicles. The
most important features of LNA-based drugs include excellent specificity providing
optimal targeting; increased affinity to targets providing improved potency; and
favorable pharmacokinetic and tissue-penetrating properties that allow systemic delivery
of these drugs without complex and potentially troublesome delivery vehicles.

About Santaris Pharma A/S

Santaris Pharma A/S is a privately held clinical-stage biopharmaceutical company focused
on the discovery and development of RNA-targeted therapies. The LNA Drug Platform and
Drug Discovery Engine developed by Santaris Pharma A/S combine the company's proprietary
LNA chemistry with its highly specialized and targeted drug development capabilities to
rapidly deliver potent single-stranded LNA-based drug candidates across a multitude of
disease states. The company's research and development activities focus on infectious
diseases and cardiometabolic disorders, while partnerships with major pharmaceutical
companies include a range of therapeutic areas including cancer, cardiovascular disease,
infectious and inflammatory diseases, and rare genetic disorders. The company has
strategic partnerships with miRagen Therapeutics, Shire PLC, Pfizer, GlaxoSmithKline,
and Enzon Pharmaceuticals. As part of its broad patent estate, the company holds
exclusive worldwide rights to manufacture, have manufactured and sell products that
contain LNA as an active ingredient for studies performed with a view to obtaining
marketing approval. Santaris Pharma A/S, founded in 2003, is headquartered in Denmark
with operations in the United States. Please visit www.santaris.com
[http://www.santaris.com/] for more information.

Santaris Pharma Forward-Looking Statements

This written announcement contains forward-looking statements, identified by the use of
words such as "believes," "expects," "may," "will," "should", "potential,"
"anticipates," "plans" or "intends" and similar expressions. Such forward-looking
statements involve risks, uncertainties and other factors that may cause actual results,
events or developments to be materially different from the future results, events or
developments indicated in this announcement. Such factors include, but are not limited
to the timing, success and cost of clinical studies; the ability to obtain regulatory
approval of products, market acceptance of and future demand for Santaris Pharma
products and the impact of competitive products and pricing. These factors should be
considered carefully and readers are cautioned not to place undue reliance on such
forward-looking statements. No assurance can be given that the future results covered by
the forward-looking statements will be achieved. All information in this press release
is as of the date of this press release and Santaris Pharma does not intend to update
this information.



Photo:  http://photos.prnewswire.com/prnh/20100111/SPLOGOPRN Photo Desk,
photodesk@prnewswire.comSantaris Pharma A/S

CONTACT:  Henrik Stage, President & CEO, Cell, (+45) 4026 0900,
hs@santaris.com; or Henrik Oerum, CSO & VP Business Development, Cell, +45
2834 6474, hoe@santaris.com

Web site:  http://www.santaris.com/
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.